Charles River Laboratories International, Inc. (CRL) Stock Price & Analysis
Charles River Laboratories International, Inc. (CRL) rose 1.83% to USD 189.85 as of June 9, 2026 at 23:41 UTC, according to Nexqual real-time market data.
CRL last closed at USD 186.44; the session ranged USD 184.91–193.17 on volume of 615,160 shares. Market capitalization is $9.14B, with a 52-week range of USD 143.06–228.88 (NYQ). Source: Nexqual, June 9, 2026 at 23:41 UTC.
Key Statistics (as of June 9, 2026 at 23:41 UTC)
| Price | USD 189.85 |
|---|---|
| Change | ▲ 1.83% (up) |
| Previous Close | USD 186.44 |
| Open | USD 188.5 |
| Day Range | USD 184.91 – 193.17 |
| 52-Week Range | USD 143.06 – 228.88 |
| Volume | 615,160 shares |
| Market Cap | $9.14B |
| Exchange | NYQ |
Technical Analysis (CRL)
Nexqual's technical model rates CRL "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 23:41 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.7 (neutral) |
| vs SMA50 | Above (USD 172.39) |
| MACD | 4.7 (positive) |
Analyst Ratings (CRL)
Wall Street analysts rate CRL "Buy" based on 15 analysts, with a mean price target of USD 212.27 (range USD 135–265), per Nexqual as of June 9, 2026 at 23:41 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 212.27 |
| High Target | USD 265 |
| Low Target | USD 135 |
| Buy / Hold / Sell | 13 / 3 / 1 |
Earnings (CRL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 2.73 |
| Revenue Estimate | $975.09M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.06 vs est 1.95 ▲ beat |
| 2025-12-31 | USD 2.39 vs est 2.35 ▲ beat |
| 2025-09-30 | USD 2.43 vs est 2.34 ▲ beat |
| 2025-06-30 | USD 3.12 vs est 2.55 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:41 UTC.
Financials & Fundamentals (CRL)
| Total Revenue | $4.03B |
|---|---|
| Revenue Growth (YoY) | +1.20% |
| Gross Margin | +34.46% |
| Operating Margin | +15.92% |
| Profit Margin | -4.58% |
| ROE | -5.87% |
| Debt / Equity | 102.55 |
| Current Ratio | 1.36 |
| Total Cash | $191.83M |
| Total Debt | $3.06B |
| Free Cash Flow | $510.02M |
Source: Nexqual, June 9, 2026 at 23:41 UTC.
Financial Health Score (CRL)
Nexqual rates Charles River Laboratories International, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:41 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 34%, operating 16% |
| Balance Sheet | Mixed — $192M cash vs $3.06B debt |
| Cash Flow | Solid — FCF $510M, 13% margin |
| Efficiency | Critical — ROE -6%, ROA 4.3% |
Ownership (CRL)
| Insider Ownership | +1.00% |
|---|---|
| Institutional Ownership | +123.42% |
| Shares Outstanding | 48.17M |
| Float | 47.58M |
| Short % of Float | +8.70% |
Source: Nexqual, June 9, 2026 at 23:41 UTC.
Leadership (CRL)
Charles River Laboratories International, Inc. is led by Birgit Girshick (age 55), CEO & Director, per Nexqual as of June 9, 2026 at 23:41 UTC.
| CEO & Director | Birgit Girshick (age 55) |
|---|---|
| Corporate Executive Vice President of Corporate Development & Strategy | Joseph W. LaPlume (age 51) |
| Corporate Executive VP & CFO | Glenn G. Coleman (age 57) |
| Corporate Senior VP & Chief Scientific Officer | Julie Frearson |
| Corporate Vice President of Investor Relations | Todd Spencer |
Major Backers & Investors (CRL)
Notable institutional backers of Charles River Laboratories International, Inc. include Harris Associates L.P., FMR, LLC, Invesco, according to Nexqual as of June 9, 2026 at 23:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Harris Associates L.P. | 7.37% |
| FMR, LLC | 7.18% |
| Invesco | 7.05% |
| Allspring Global Investments Holdings, LLC | 4.14% |
| Wellington Management | 3.38% |
| AIM Sector Funds (Invesco Sector Funds)-INVESCO SMALL CAP VALUE FUND | 3.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.12% |
| BlackRock | 8.01% |
| State Street | 3.89% |
| Dimensional Fund Advisors | 3.43% |
Source: Nexqual, June 9, 2026 at 23:41 UTC.
From Charles River Laboratories International, Inc.'s Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
- The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
- This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies.
- The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services.
Partnerships
- Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TECH | Bio-Techne Corp | USD 54.41 | ▲ 4.65% |
| IQV | IQVIA Holdings, Inc. | USD 186.25 | ▲ 1.53% |
| COO | The Cooper Companies, Inc. | USD 68.62 | ▲ 1.9% |
| BIO | Bio-Rad Laboratories, Inc. | USD 297.17 | ▲ 0.97% |
| WST | West Pharmaceutical Services, I | USD 334.66 | ▲ 6.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:41 UTC. This page is informational and not investment advice.